Success Metrics

Clinical Success Rate
85.5%

Based on 47 completed trials

Completion Rate
85%(47/55)
Active Trials
0(0%)
Results Posted
26%(12 trials)
Terminated
8(15%)

Phase Distribution

Ph phase_1
33
60%
Ph phase_2
22
40%

Phase Distribution

33

Early Stage

22

Mid Stage

0

Late Stage

Phase Distribution55 total trials
Phase 1Safety & dosage
33(60.0%)
Phase 2Efficacy & side effects
22(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.5%

47 of 55 finished

Non-Completion Rate

14.5%

8 ended early

Currently Active

0

trials recruiting

Total Trials

55

all time

Status Distribution
Completed(47)
Terminated(8)

Detailed Status

Completed47
Terminated8

Development Timeline

Analytics

Development Status

Total Trials
55
Active
0
Success Rate
85.5%
Most Advanced
Phase 2

Trials by Phase

Phase 133 (60.0%)
Phase 222 (40.0%)

Trials by Status

completed4785%
terminated815%

Recent Activity

0 active trials
Showing 5 of 55
terminatedphase_2

Alvocidib Biomarker-driven Phase 2 AML Study

NCT02520011
completedphase_1

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

NCT03298984
completedphase_1

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

NCT03563560
completedphase_1

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT03441555
completedphase_2

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

NCT00005971
View all 55 trials

Clinical Trials (55)

Showing 20 of 55 trialsScroll for more
NCT02520011Phase 2

Alvocidib Biomarker-driven Phase 2 AML Study

Terminated
NCT03298984Phase 1

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

Completed
NCT03563560Phase 1

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Completed
NCT03441555Phase 1

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Completed
NCT00005971Phase 2

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Completed
NCT00005074Phase 2

Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma

Completed
NCT00005974Phase 2

Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Completed
NCT00795002Phase 2

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
NCT01349972Phase 2

Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
NCT00058240Phase 1

Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Completed
NCT00098371Phase 2

Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Terminated
NCT00112723Phase 1

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Terminated
NCT00407966Phase 2

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
NCT00634244Phase 2

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed
NCT00019344Phase 1

Flavopiridol in Treating Patients With Refractory Cancer

Completed
NCT00331682Phase 2

Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

Completed
NCT00991952Phase 2

Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery

Completed
NCT00083122Phase 2

Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed
NCT00112684Phase 1

Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Terminated
NCT00324480Phase 1

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Completed

Drug Details

Intervention Type
DRUG
Total Trials
55